

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN	MOTEXAFIN LUTETIUM
PRONUNCIATION	moe teks' a fin
THERAPEUTIC CLAIMS	antineoplastic/antiatherosclerotic

CHEMICAL NAMES

- (1) lutetium, bis(acetato- $\kappa O$ )[9,10-diethyl-20,21-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanolato- $\kappa N^1, \kappa N^{18}, \kappa N^{23}, \kappa N^{24}, \kappa N^{25}$ ]-, hydrate, (PB-7-11-233'2'4)-
- (2) bis(acetato- $O$ )[9,10-diethyl-20,21-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanolato- $N^1, N^{18}, N^{23}, N^{24}, N^{25}$ ]-, hydrate, (PB-7-11-233'2'4)-

STRUCTURAL FORMULA

(See page 2)

MOLECULAR FORMULA	$C_{52}H_{72}LuN_5O_{14} \cdot xH_2O$ , where x is typically between 0 and 2
MOLECULAR WEIGHT	1166.1 (anhydrous)
TRADEMARKS	Lutrin®, Antrin®, Optrin™
MANUFACTURER	Pharmacyclics, Inc.
CODE DESIGNATIONS	PCI-0123; lutetium texaphyrin, Lu texaphyrin, Lu-Tex; FP-LP1
<u>CAS</u> REGISTRY NUMBER	156436-90-7

MOTEXAFIN LUTETIUM

STRUCTURAL FORMULA

